EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF COVID-19 RAPID ANTIGEN TEST IN COMPARISON TO SARS-COV-2 REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION

Öz

Objective: The World Health Organization recommends reverse transcriptase polymerase chain reaction (RT-PCR) as the reference method for COVID-19 diagnosis. However, it is time- consuming, costly, and requires specialized equipment and trained personnel. Therefore, rapid antigen tests (RATs), which provide results within 15–30 minutes, have emerged as a potential alternative. The aim of the current study was to assess the diagnostic performance of the SARS-CoV-2 Rapid Antigen Test (Ref No: 9901-NCOV-01G, Roche Diagnostics) compared to RT-PCR in adult patients with COVID-19-related symptoms. Material and Methods: In this prospective observational study, 492 symptomatic adult patients, aged ≥ 18 years, were tested using simultaneous oro-nasopharyngeal swabs for RAT and RT- PCR. Diagnostic metrics were calculated, and the impact of cycle threshold (Ct) values and symptom duration on RAT performance was analyzed. Results: In total, 167 (33.9%) of 492 patients’ oro- nasopharyngeal swab samples tested by RT-PCR result were positive. Compared to RT-PCR, the sensitivity, specificity, positive and negative predictive value of RAT were 90.4% [95% confidence interval (CI): 85%-94%], 98.8% (95% CI: 96.9%-99.5%), 97.4% (95% CI: 93.6%-99%) and 95.3% (95% CI: 92.4%-97.1%), respectively. The Ct values of samples with false-negative RAT results were higher than the samples that tested positive by RAT and RT-PCR [23.93±4.40) vs. 18.42±4.56), p<0.001]. Based on the Ct values, RAT sensitivity was 96.5%, 80.5%, and 30.8% for the <22, 22-26, and >26 groups, respectively. Furthermore, as Ct values increased, RAT was less likely to detect SARS-CoV-2 infection (p<0.001). Conclusion: The SARS-CoV-2 RAT exhibited high diagnostic performance in symptomatic patients and exceeded the minimum sensitivity and specificity thresholds recommended by the World Health Organization. Although its sensitivity decreases with higher Ct values, which may reflect lower viral loads, RAT remains a valuable point-of-care tool for early detection and isolation of COVID-19 cases. Confirmatory RT- PCR testing should be considered in symptomatic patients with negative RAT results.

Anahtar Kelimeler

• COVID-19
• diagnostic accuracy
• rapid antigen test
• SARS-CoV-2

COVID-19 Hızlı Antijen Testinin Sars-Cov-2 Reverz Transkriptaz Polimeraz Zincir Reaksiyonu İle Karşılaştırmalı Tanısal Performansının Değerlendirilmesi

Öz

Amaç: Dünya Sağlık Örgütü, COVID-19 tanısında referans yöntem olarak reverz transkriptaz polimeraz zincir reaksiyonunu (RT-PZR) önermektedir. Ancak bu yöntem; zaman alıcı ve maliyetli olup özel donanım ve eğitimli personel gerektirmektedir. Bu nedenle, hızlı antijen testleri (HAT) potansiyel bir alternatif olarak öne çıkmıştır. Bu çalışmanın amacı, COVID-19 ile ilişkili semptomları olan erişkin hastalarda SARS-CoV-2 Hızlı Antijen Testi'nin (Ref No: 9901- NCOV-01G, Roche Diagnostics) RT-PZR ile karşılaştırmalı tanısal performansını değerlendirmektir. Gereç ve Yöntemler: Bu prospektif gözlemsel çalışmada, 492 semptomatik erişkin hastadan eş zamanlı olarak alınan oro- nazofarengeal sürüntüler HAT ve RT-PZR yöntemleriyle test edilmiştir. Tanısal ölçütler hesaplanmış ve döngü eşiği (Ct) değerlerinin ve semptom süresinin HAT performansı üzerindeki etkisi analiz edilmiştir. Bulgular: RT-PZR ile test edilen 492 hastanın 167’sinde (%33,9) oro-nazofarengeal sürüntü örnekleri pozitif bulunmuştur. RT-PZR ile karşılaştırıldığında, HAT’in duyarlılığı %90,4 [güven aralığı (GA) %95: %85–%94], özgüllüğü %98,8 (GA %95: %96,9–%99,5), pozitif prediktif değeri %97,4 (GA %95: %93,6–%99) ve negatif prediktif değeri %95,3 (GA %95: %92,4–%97,1) olarak hesaplanmıştır. Yanlış negatif HAT sonuçlarına sahip örneklerin Ct değerleri, her iki yöntemle de pozitif saptanan örneklere kıyasla daha yüksek bulunmuştur [23,93±4,40) vs. 18,42±4,56), p<0,001]. Ct değerlerine göre HAT’in duyarlılığı <22, 22–26 ve >26 grupları için sırasıyla %96,5, %80,5 ve %30,8 olarak saptanmıştır. Ayrıca, Ct değeri arttıkça HAT’in SARS-CoV-2 enfeksiyonunu saptama olasılığı anlamlı şekilde azalmıştır (p<0,001). Sonuç: SARS-CoV-2 Hızlı Antijen Testi, semptomatik hastalarda yüksek tanısal performans göstermiş ve Dünya Sağlık Örgütü tarafından önerilen minimum duyarlılık ve özgüllük eşiklerinin üzerinde bulunmuştur. Ct değerinin artmasıyla, ki bu durum viral yükün azalmasını yansıtmaktadır, testin duyarlılığı düşse de HAT COVID-19 olgularının erken saptanması ve izolasyonu açısından değerli bir başvuru testi olarak ön plana çıkmaktadır. Semptomatik hastalarda negatif HAT sonucu alınması durumunda sonucun RT-PZR testi ile doğrulanması önerilmektedir.

Anahtar Kelimeler

• COVID-19
• tanısal doğruluk
• hızlı antijen testi
• SARS-CoV-2

Kaynakça

1. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. Accessed date: 21 January 2025: https://data.who.int/dashboards/covid19/deaths?n=c
2. T.C. Sağlık Bakanlığı. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu. Accessed date: 21 January 2025: https://covid19.saglik.gov.tr
3. Albert E, Torres I, Bueno F, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021;27(3):472.e7-472.e10.
4. da Silva SJR, Silva CTAD, Guarines KM, et al. Clinical and laboratory diagnosis of SARS-CoV-2, the Virus Causing COVID-19. ACS Infect Dis. 2020;6(9):2319-2336.
5. Gupta A, Khurana S, Das R, et al. Rapid chromatographic immunoassay-based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India. Indian J Med Res. 2021;153(1 & 2):126-131.
6. Rai P, Kumar BK, Deekshit VK, Karunasagar I, Karunasagar I. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl Microbiol Biotechnol. 2021;105(2):441-455.
7. World Health Organization (WHO). Antigen-detection in the diagnosis of SARS-CoV-2 infection – Interim guidance 2021. Accessed date: 21 January 2025: https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays
8. Elli S, Blasi F, Brignolo B, et al. Diagnostic accuracy of rapid antigen test for COVID-19 in an emergency department. Diagn Microbiol Infect Dis. 2022;102(4):115635.

9. US Food and Drug Administration. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices. Accessed date: 21 January 2025: https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices
10. Seitz T, Lickefett B, Traugott M, et al. Evaluation of five commercial SARS-CoV-2 antigen tests in a clinical setting. J Gen Intern Med. 2022;37(6):1494-1500.
11. Arshadi M, Fardsanei F, Deihim B, et al. Diagnostic accuracy of rapid antigen tests for COVID-19 detection: A systematic review with meta-analysis. Front Med (Lausanne). 2022;9:870738.
12. Dinnes J, Deeks JJ, Adriano A, et al; Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020;8(8):CD013705. Update in: Cochrane Database Syst Rev. 2021;3:CD013705.
13. Heydecke A, Gullsby K. Evaluation of the performance of a rapid antigen test (Roche) for COVID-19 diagnosis in an emergency setting in Sweden. J Med Virol. 2023;95(2):e28537.
14. Pérez-García F, Romanyk J, Moya Gutiérrez H, et al. Comparative evaluation of Panbio and SD Biosensor antigen rapid diagnostic tests for COVID-19 diagnosis. J Med Virol. 2021;93(9):5650-5654.
15. Gobena D, Gudina EK, Gebre G, Degfie TT, Mekonnen Z. Rapid antigen test as a screening tool for SARS-CoV-2 infection: Head-to-head comparison with qRT-PCR in Ethiopia. Heliyon. 2023;10(1):e23518.
16. Xie JW, He Y, Zheng YW, Wang M, Lin Y, Lin LR. Diagnostic accuracy of rapid antigen test for SARS-CoV-2: A systematic review and meta-analysis of 166,943 suspected COVID-19 patients. Microbiol Res. 2022;265:127185.
17. Kahn M, Schuierer L, Bartenschlager C, et al. Performance of antigen testing for diagnosis of COVID-19: a direct comparison of a lateral flow device to nucleic acid amplification based tests. BMC Infect Dis. 2021;21(1):798.
18. Torjesen I. Covid-19: How the UK is using lateral flow tests in the pandemic. BMJ. 2021;372:n287. Erratum in: BMJ. 2021;373:n1620.
19. Thommes L, Burkert FR, Öttl KW, et al. Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients. Int J Infect Dis. 2021;105:144-146.
20. Corman VM, Haage VC, Bleicker T, et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. Lancet Microbe. 2021;2(7):e311-e319.
21. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-469. Erratum in: Nature. 2020;588(7839):E35.
22. Mandal DK, Bhattarai BR, Pokhrel S, , et al. Diagnostic performance of SARS-CoV-2 rapid antigen test in relation to RT-PCR Cq Value. Adv Virol. 2022;2022:9245248.
23. Dhakal S, Karki S. Early Epidemiological features of COVID-19 in Nepal and public health response. Front Med (Lausanne). 2020;7:524.
24. Dinnes J, Sharma P, Berhane S, et al; Cochrane COVID-19 diagnostic test accuracy group. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2022;7(7):CD013705.
25. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral load in upper respiratory specimens of ınfected patients. N Engl J Med. 2020;382(12):1177-1179.
26. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25(32):2001483. Erratum in: Euro Surveill. 2021;26(7).
27. Wagenhäuser I, Knies K, Pscheidl T, et al. SARS-CoV-2 antigen rapid detection tests: test performance during the COVID-19 pandemic and the impact of COVID-19 vaccination. EBioMedicine. 2024;109:105394.
28. Kim AE, Bennett JC, Luiten K, et al. Comparative diagnostic utility of SARS-CoV-2 rapid antigen and molecular testing in a community setting. J Infect Dis. 2024;230(2):363-373.